Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC
Submission relating to ofatumumab (Kesimpta®) to PBAC meeting March 20242024-01-312024-09-05https://msra.org.au/wp-content/uploads/2016/03/MSRA-logo.jpgMS Australiahttps://www.msaustralia.org.au/wp-content/uploads/2021/09/ms-australia-tag-line-1-1.png200px200px
